Candel Therapeutics Q2 EPS $(0.74) Down From $(0.33) YoY
Portfolio Pulse from Benzinga Newsdesk
Candel Therapeutics (NASDAQ:CADL) reported a significant increase in quarterly losses, with Q2 EPS at $(0.74), down from $(0.33) YoY, marking a 124.24% decrease.

August 13, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Candel Therapeutics reported a significant increase in quarterly losses, with Q2 EPS at $(0.74), down from $(0.33) YoY, marking a 124.24% decrease.
The significant increase in quarterly losses is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100